1. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
- Author
-
Shasha Wang, Jianliang Yang, Le Tang, Qiaoyun Tan, Puyuan Xing, Yanrong Wang, Liyuan Dai, Xingsheng Hu, Shengyu Zhou, Yuankai Shi, Te Liang, Xiaohong Han, Haizhu Chen, Rongrong Luo, Xiaobo Yu, Zhishang Zhang, Yutao Liu, Yu Zhou, Di Wu, Ning Lou, Jiarui Yao, Qiaofeng Zhong, and Shuxia Liu
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Immunology ,B7-H1 Antigen ,Subclass ,Immune system ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Autoantibodies ,biology ,business.industry ,Autoantibody ,Cancer ,medicine.disease ,Lymphoma ,Immunoglobulin G ,Cohort ,biology.protein ,Biomarker (medicine) ,Antibody ,business ,Biomarkers - Abstract
Antibodies targeting programmed cell death-1(PD1) and its ligand (PDL1) have revolutionized cancer therapy. However, little is known about the preexisted anti-PD1/PDL1 autoantibodies (AAbs) distribution in multiple cancer types, nor is their potential biomarker role for anti-PD1 therapy. Plasma anti-PD1/PDL1 AAb IgG and subclasses (IgG1-4) were detected by enzyme-linked immune sorbent assay (ELISA) in 190 cancer patients, covering 10 cancer types (lung, breast, esophageal, colorectal, liver, prostatic, cervical, ovarian, gastric cancers and lymphoma), the comprehensive correlation of AAbs with multiple clinical parameters was analyzed. We further tested these AAbs in 76 non-small cell lung cancer (NSCLC) samples receiving anti-PD1 therapy, the association of AAbs level with survival was analyzed and validated in an independent cohort (n = 32). Anti-PD1/PDL1 AAb IgG were globally detected in 10 types of cancer patients. IgG1 and IgG2 were the major subtypes for anti-PD1/PDL1 AAbs. Correlation analysis revealed a distinct landscape between various cancer types. The random forest model indicated that IgG4 subtype was mostly associated with cancer. In discovery cohort of 76 NSCLC patients, high anti-PD1 IgG4 was associated with a reduced overall survival (OS, p = 0.019), not progression-free survival (PFS, p = 0.088). The negative association of anti-PD1 IgG4 with OS was validated in 32 NSCLC patients (p = 0.032). This study reports for the first time the distribution of preexisted anti-PD1/PDL1 AAb IgG and subclasses across 10 cancer types. Moreover, the anti-PD1 AAb IgG4 subclass was identified to associate with OS, which may serve as a potential biomarker for anti-PD1 therapeutic survival benefit in NSCLC patients.
- Published
- 2021